218 related articles for article (PubMed ID: 17845905)
1. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis.
Balatoni B; Storch MK; Swoboda EM; Schönborn V; Koziel A; Lambrou GN; Hiestand PC; Weissert R; Foster CA
Brain Res Bull; 2007 Oct; 74(5):307-16. PubMed ID: 17845905
[TBL] [Abstract][Full Text] [Related]
2. FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses.
Papadopoulos D; Rundle J; Patel R; Marshall I; Stretton J; Eaton R; Richardson JC; Gonzalez MI; Philpott KL; Reynolds R
J Neurosci Res; 2010 Feb; 88(2):346-59. PubMed ID: 19658199
[TBL] [Abstract][Full Text] [Related]
3. Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis.
Chiba K; Kataoka H; Seki N; Shimano K; Koyama M; Fukunari A; Sugahara K; Sugita T
Int Immunopharmacol; 2011 Mar; 11(3):366-72. PubMed ID: 20955831
[TBL] [Abstract][Full Text] [Related]
4. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration.
Kataoka H; Sugahara K; Shimano K; Teshima K; Koyama M; Fukunari A; Chiba K
Cell Mol Immunol; 2005 Dec; 2(6):439-48. PubMed ID: 16426494
[TBL] [Abstract][Full Text] [Related]
5. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis.
Foster CA; Howard LM; Schweitzer A; Persohn E; Hiestand PC; Balatoni B; Reuschel R; Beerli C; Schwartz M; Billich A
J Pharmacol Exp Ther; 2007 Nov; 323(2):469-75. PubMed ID: 17682127
[TBL] [Abstract][Full Text] [Related]
6. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage.
Foster CA; Mechtcheriakova D; Storch MK; Balatoni B; Howard LM; Bornancin F; Wlachos A; Sobanov J; Kinnunen A; Baumruker T
Brain Pathol; 2009 Apr; 19(2):254-66. PubMed ID: 18540945
[TBL] [Abstract][Full Text] [Related]
7. Central nervous system-directed effects of FTY720 (fingolimod).
Miron VE; Schubart A; Antel JP
J Neurol Sci; 2008 Nov; 274(1-2):13-7. PubMed ID: 18678377
[TBL] [Abstract][Full Text] [Related]
8. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment.
Fujino M; Funeshima N; Kitazawa Y; Kimura H; Amemiya H; Suzuki S; Li XK
J Pharmacol Exp Ther; 2003 Apr; 305(1):70-7. PubMed ID: 12649354
[TBL] [Abstract][Full Text] [Related]
9. Relapse of experimental autoimmune encephalomyelitis after discontinuation of FTY720 (Fingolimod) treatment, but not after combination of FTY720 and pathogenic autoantigen.
Yoshida Y; Tsuji T; Fujita T; Kohno T
Biol Pharm Bull; 2011; 34(6):933-6. PubMed ID: 21628899
[TBL] [Abstract][Full Text] [Related]
10. Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo.
Hu Y; Lee X; Ji B; Guckian K; Apicco D; Pepinsky RB; Miller RH; Mi S
Mol Cell Neurosci; 2011 Sep; 48(1):72-81. PubMed ID: 21740973
[TBL] [Abstract][Full Text] [Related]
11. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Chiba K; Adachi K
Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
[TBL] [Abstract][Full Text] [Related]
12. [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
Tar L; Vécsei L
Ideggyogy Sz; 2012 Mar; 65(3-4):83-100. PubMed ID: 23136726
[TBL] [Abstract][Full Text] [Related]
13. Focal experimental autoimmune encephalomyelitis in the Lewis rat induced by immunization with myelin oligodendrocyte glycoprotein and intraspinal injection of vascular endothelial growth factor.
Sasaki M; Lankford KL; Brown RJ; Ruddle NH; Kocsis JD
Glia; 2010 Oct; 58(13):1523-31. PubMed ID: 20645414
[TBL] [Abstract][Full Text] [Related]
14. Methylprednisolone induces reversible clinical and pathological remission and loss of lymphocyte reactivity to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis.
Chan J; Ban EJ; Chun KH; Wang S; McQualter J; Bernard C; Toh BH; Alderuccio F
Autoimmunity; 2008 Aug; 41(5):405-13. PubMed ID: 18568646
[TBL] [Abstract][Full Text] [Related]
15. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
[TBL] [Abstract][Full Text] [Related]
16. Autoimmunity against myelin oligodendrocyte glycoprotein is dispensable for the initiation although essential for the progression of chronic encephalomyelitis in common marmosets.
Jagessar SA; Smith PA; Blezer E; Delarasse C; Pham-Dinh D; Laman JD; Bauer J; Amor S; 't Hart B
J Neuropathol Exp Neurol; 2008 Apr; 67(4):326-40. PubMed ID: 18379435
[TBL] [Abstract][Full Text] [Related]
17. Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.
Colombo E; Di Dario M; Capitolo E; Chaabane L; Newcombe J; Martino G; Farina C
Ann Neurol; 2014 Sep; 76(3):325-37. PubMed ID: 25043204
[TBL] [Abstract][Full Text] [Related]
18. Diffusion tensor imaging detects treatment effects of FTY720 in experimental autoimmune encephalomyelitis mice.
Wang X; Brieland JK; Kim JH; Chen YJ; O'Neal J; O'Neil SP; Tu TW; Trinkaus K; Song SK
NMR Biomed; 2013 Dec; 26(12):1742-50. PubMed ID: 23939596
[TBL] [Abstract][Full Text] [Related]
19. FTY720 (fingolimod) for relapsing multiple sclerosis.
Horga A; Montalban X
Expert Rev Neurother; 2008 May; 8(5):699-714. PubMed ID: 18457527
[TBL] [Abstract][Full Text] [Related]
20. Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis.
Zagon IS; Rahn KA; Bonneau RH; Turel AP; McLaughlin PJ
Brain Res; 2010 Jan; 1310():154-61. PubMed ID: 19931226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
